Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Transitional Cell Carcinoma of Bladder Clinical Trial

Official title:
Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Status Completed

Clinical Trial Summary

- Safety and tolerability of three regimens of intravesically administered BC-819/PEI and BCG (number of participants with AEs, discontinuations due to AEs)

- Recurrence after treatment with BC-819/PEI and BCG

- Approximately 38 patients with superficial transitional cell carcinoma TCC) of the bladder

- After initial evaluation and qualification, patients will be randomized to one of three treatment groups, either alternating, sequential or twice weekly

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Transitional Cell
Transitional Cell Carcinoma of Bladder
Urinary Bladder Neoplasms

Clinical Trial Details

NCT number	NCT01878188
Study type	Interventional
Source	Anchiano Therapeutics Israel Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	February 2013
Completion date	October 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01326871` - A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer	Phase 1/Phase 2
Recruiting	`NCT05902988` - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/Phase 2
Completed	`NCT01135849` - B-Receptor Signaling in Cardiomyopathy	N/A
Completed	`NCT01620970` - PF-03446962 in Relapsed or Refractory Urothelial Cancer	Phase 2
Completed	`NCT00734994` - Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer	Phase 0